ClinVar Miner

Submissions for variant NM_000059.3(BRCA2):c.4578A>G (p.Thr1526=) (rs202022822)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) RCV000495149 SCV000578012 benign Breast-ovarian cancer, familial 2 2017-06-29 reviewed by expert panel curation Synonymous substitution variant, with low bioinformatic likelihood to alter mRNA splicing (splicing prior 0.02; and frequency 0.0024 (East Asian), derived from ExAC (2014-12-17).
Ambry Genetics RCV000163588 SCV000214148 likely benign Hereditary cancer-predisposing syndrome 2014-07-03 criteria provided, single submitter clinical testing This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.
Invitae RCV001084558 SCV000261061 benign Hereditary breast and ovarian cancer syndrome 2020-12-06 criteria provided, single submitter clinical testing
Laboratory of Molecular Diagnosis of Cancer,West China Hospital, Sichuan University RCV000240740 SCV000265953 uncertain significance Breast neoplasm 2015-11-01 criteria provided, single submitter research
GeneDx RCV000588843 SCV000515708 likely benign not provided 2020-01-28 criteria provided, single submitter clinical testing This variant is associated with the following publications: (PMID: 18431501, 18627636, 27257965, 21601571, 19747923, 10323242)
Color Health, Inc RCV000163588 SCV000683631 likely benign Hereditary cancer-predisposing syndrome 2016-02-17 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000588843 SCV000694783 likely benign not provided 2017-01-18 criteria provided, single submitter clinical testing Variant summary: The BRCA2 c.4578A>G (p.Thr1526Thr) variant causes a synonymous change involving a non-conserved nucleotide, 2/5 programs in Alamut predict that this variant may generate a novel 3' splicing acceptor site, one program also predicts the wild-type allele of this variant may generate the same 3' splicing acceptor site, suggesting this predicted effect is unlikely associated with the disease. However, these predictions have yet to be confirmed by functional studies. The variant of interest was observed in a large, broad control population, ExAC, with an allele frequency of 19/120502 (1/6369), predominantly in the East Asian cohort, 19/8642 (1/454), which exceeds the estimated maximal expected allele frequency for a pathogenic BRCA2 variant of 1/3333. Therefore, suggesting this is likely a benign polymorphism found primarily in population(s) of East Asian origin. Multiple publications have cited the variant in affected individuals, however, with limited available information (ie, lack of co-occurrence and cosegregation data). Multiple clinical diagnostic laboratories/reputable databases have classified the variant from "uncertain significance" to "likely benign/benign." Therefore, the variant of interest has been classified as "Likely Benign."
Department of Pathology and Laboratory Medicine,Sinai Health System RCV000427408 SCV000591910 benign not specified no assertion criteria provided clinical testing The p.Thr1526Thr variant is not expected to have clinical significance because it does not alter an amino acid residue and is not located near a splice junction. The variant has been reported in the literature in 3/472 proband chromosomes from individuals with breast cancer; however, no control chromosomes were tested to establish the frequency of the variant in the general population (Lin_2009, Thirthagiri_2008, Toh_2008). Studies examining the crystal structure of the residue as well as functional studies indicate that it lies within a highly conserved region in the BRC domains of BRCA2 that is involved in the interaction with Rad51, and that it participates in hydrogen bond stabilization of the hairpin complex that forms between BRCA2 and Rad51 (Ochiai_2011, Tal_2009). This variant was previously identified by our lab in two individuals, one individual with a second pathogenic variant, increasing the likelihood this variant is benign. In summary, based on the above information, this variant is classified as benign.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.